Pipobroman

SKU: orb1222061

Description

Pipobroman is an anti-cancer drug that probably acts as an alkylating agent. Pipobroman has well documented clinical activity in polycythemia vera (PV) and essential thrombocythemia (ET). Pipobroman allows, within 3 months, to attain a response in more than 90% of patients, without clinically relevant toxicities. The 10-years risk of thrombosis of patients treated with Pipobroman is about 15%, The anti-proliferative activity of Pipobroman on bone marrow megakaryocytes seems of particular value in lowering the occurrence of post-PV and post-ET MMM, whose risk is the lowest registered with available treatments. The 10-year risk of acute leukemia with Pipobroman is 5% in PVand 3% in ET, which is only slightly higher than that expected as a natural evolution of the disease. In conclusion, the use of Pipobroman is a definite alternative to hydroxyurea in patients with PV and ET at high risk of thrombosis.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 54-91-1
• MW: 356.06
• Purity: >98% (HPLC)
• Formula: C₁₀H₁₆Br₂N₂O₂
• SMILES: BrCCC(=O)N1CCN(CC1)C(=O)CCBr
• Target: Apoptosis
• Solubility: DMSO : ≥ 36 mg/mL; 101.11 mM

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

NSC25154 | Pipobroman

Quick Database Links

Gene Symbol

Apoptosis